Risk of pediatric celiac disease according to HLA haplotype and country
- PMID: 24988556
- PMCID: PMC4163840
- DOI: 10.1056/NEJMoa1313977
Risk of pediatric celiac disease according to HLA haplotype and country
Erratum in
- N Engl J Med. 2014 Jul 24;371(4):390
Abstract
Background: The presence of HLA haplotype DR3-DQ2 or DR4-DQ8 is associated with an increased risk of celiac disease. In addition, nearly all children with celiac disease have serum antibodies against tissue transglutaminase (tTG).
Methods: We studied 6403 children with HLA haplotype DR3-DQ2 or DR4-DQ8 prospectively from birth in the United States, Finland, Germany, and Sweden. The primary end point was the development of celiac disease autoimmunity, which was defined as the presence of tTG antibodies on two consecutive tests at least 3 months apart. The secondary end point was the development of celiac disease, which was defined for the purpose of this study as either a diagnosis on biopsy or persistently high levels of tTG antibodies.
Results: The median follow-up was 60 months (interquartile range, 46 to 77). Celiac disease autoimmunity developed in 786 children (12%). Of the 350 children who underwent biopsy, 291 had confirmed celiac disease; an additional 21 children who did not undergo biopsy had persistently high levels of tTG antibodies. The risks of celiac disease autoimmunity and celiac disease by the age of 5 years were 11% and 3%, respectively, among children with a single DR3-DQ2 haplotype, and 26% and 11%, respectively, among those with two copies (DR3-DQ2 homozygosity). In the adjusted model, the hazard ratios for celiac disease autoimmunity were 2.09 (95% confidence interval [CI], 1.70 to 2.56) among heterozygotes and 5.70 (95% CI, 4.66 to 6.97) among homozygotes, as compared with children who had the lowest-risk genotypes (DR4-DQ8 heterozygotes or homozygotes). Residence in Sweden was also independently associated with an increased risk of celiac disease autoimmunity (hazard ratio, 1.90; 95% CI, 1.61 to 2.25).
Conclusions: Children with the HLA haplotype DR3-DQ2, especially homozygotes, were found to be at high risk for celiac disease autoimmunity and celiac disease early in childhood. The higher risk in Sweden than in other countries highlights the importance of studying environmental factors associated with celiac disease. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others.).
Figures


Comment in
-
Risk of celiac disease according to HLA haplotype and country.N Engl J Med. 2014 Sep 11;371(11):1074. doi: 10.1056/NEJMc1409252. N Engl J Med. 2014. PMID: 25207776 No abstract available.
-
Risk of celiac disease according to HLA haplotype and country.N Engl J Med. 2014 Sep 11;371(11):1073. doi: 10.1056/NEJMc1409252. N Engl J Med. 2014. PMID: 25207777 No abstract available.
-
Risk of celiac disease according to HLA haplotype and country.N Engl J Med. 2014 Sep 11;371(11):1073-4. doi: 10.1056/NEJMc1409252. N Engl J Med. 2014. PMID: 25207778 No abstract available.
-
Risk of pediatric celiac disease according to HLA haplotype and country: evidence-based-medicine viewpoint.Indian Pediatr. 2014 Sep;51(9):733. doi: 10.1007/s13312-014-0492-y. Indian Pediatr. 2014. PMID: 25228608 No abstract available.
References
-
- TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr Diabetes. 2007;8:286–298. - PubMed
-
- Hoffenberg EJ, Bao F, Eisenbarth GS, et al. Transglutaminase antibodies in children with a genetic risk for celiac disease. J Pediatr. 2000;137:356–360. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 DK063821/DK/NIDDK NIH HHS/United States
- UC4 DK95300/DK/NIDDK NIH HHS/United States
- U01 DK63861/DK/NIDDK NIH HHS/United States
- UC4 DK63863/DK/NIDDK NIH HHS/United States
- U01 DK63821/DK/NIDDK NIH HHS/United States
- UC4 DK063821/DK/NIDDK NIH HHS/United States
- UC4 DK063836/DK/NIDDK NIH HHS/United States
- UC4 DK63865/DK/NIDDK NIH HHS/United States
- U01 DK063861/DK/NIDDK NIH HHS/United States
- U01 DK063790/DK/NIDDK NIH HHS/United States
- UC4 DK100238/DK/NIDDK NIH HHS/United States
- U01 DK63829/DK/NIDDK NIH HHS/United States
- UL1 TR001082/TR/NCATS NIH HHS/United States
- UC4 DK63829/DK/NIDDK NIH HHS/United States
- U01 DK63836/DK/NIDDK NIH HHS/United States
- UC4 DK63821/DK/NIDDK NIH HHS/United States
- UC4 DK063863/DK/NIDDK NIH HHS/United States
- UL1 TR000064/TR/NCATS NIH HHS/United States
- UC4 DK63836/DK/NIDDK NIH HHS/United States
- U01 DK063836/DK/NIDDK NIH HHS/United States
- U01 DK063829/DK/NIDDK NIH HHS/United States
- U01 DK063865/DK/NIDDK NIH HHS/United States
- UC4 DK095300/DK/NIDDK NIH HHS/United States
- UC4 DK063861/DK/NIDDK NIH HHS/United States
- U01 DK63865/DK/NIDDK NIH HHS/United States
- UC4 DK063829/DK/NIDDK NIH HHS/United States
- U01 DK063863/DK/NIDDK NIH HHS/United States
- U01 DK63790/DK/NIDDK NIH HHS/United States
- UC4 DK063865/DK/NIDDK NIH HHS/United States
- U01 DK63863/DK/NIDDK NIH HHS/United States
- UC4 DK63861/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials